Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The venom of Agkistrodon piscivorus (Cottonmouth) is a complex mixture of proteins that function synergistically to cause systemic and local toxicity. Major components include snake venom metalloproteinases (SVMPs), which degrade the basement membrane of blood vessels leading to hemorrhage, and phospholipases A2 (PLA2s), which cause myonecrosis and inflammation (Lomonte et al., 2014). Serine proteases in the venom act as thrombin-like enzymes, depleting fibrinogen and causing venom-induced consumptive coagulopathy, while L-amino-acid oxidases contribute to tissue damage through the production of reactive oxygen species and induction of apoptosis (Sunagar et al., 2015). Disintegrins are also present, which inhibit platelet aggregation by competitively binding to the integrin alpha-IIb-beta-3 receptor (UniProt, 2023). These proteins are the primary therapeutic targets for antivenoms like CroFab and Anavip, which utilize purified antibody fragments to sequester and neutralize the toxins (FDA, 2018). Beyond their role in envenomation, these proteins have been studied as molecular templates for developing anticoagulants and anti-cancer agents due to their high specificity for physiological receptors. Clinical management of envenomation requires monitoring of hematologic parameters to assess the efficacy of neutralization. The diversity of these proteins necessitates a polyvalent approach to treatment to ensure all toxic components are addressed.
Neutralization of toxic enzymatic and non-enzymatic activities through antibody binding, preventing interaction with host substrates and receptors (FDA, 2018).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Agkistrodon piscivorus venom proteins.